PT - JOURNAL ARTICLE AU - Mutesa, Leon AU - Ndishimye, Pacifique AU - Butera, Yvan AU - Souopgui, Jacob AU - Uwineza, Annette AU - Rutayisire, Robert AU - Musoni, Emile AU - Rujeni, Nadine AU - Nyatanyi, Thierry AU - Ntagwabira, Edouard AU - Semakula, Muhammed AU - Musanabaganwa, Clarisse AU - Nyamwasa, Daniel AU - Ndashimye, Maurice AU - Ujeneza, Eva AU - Mwikarago, Ivan Emile AU - Muvunyi, Claude Mambo AU - Mazarati, Jean Baptiste AU - Nsanzimana, Sabin AU - Turok, Neil AU - Ndifon, Wilfred TI - A strategy for finding people infected with SARS-CoV-2: optimizing pooled testing at low prevalence AID - 10.1101/2020.05.02.20087924 DP - 2020 Jan 01 TA - medRxiv PG - 2020.05.02.20087924 4099 - http://medrxiv.org/content/early/2020/05/19/2020.05.02.20087924.short 4100 - http://medrxiv.org/content/early/2020/05/19/2020.05.02.20087924.full AB - Suppressing SARS-CoV-2 will likely require the rapid identification and isolation of infected individuals, on an ongoing basis. RT-PCR (reverse transcription polymerase chain reaction) tests are accurate but costly, making regular testing of every individual expensive. The costs are a challenge for all countries and particularly for developing countries. Cost reductions can be achieved by combining samples and testing them in groups. We propose an algorithm for grouping subsamples, prior to testing, based on the geometry of a hypercube. At low prevalence, this testing procedure uniquely identifies infected individuals in a small number of tests. We discuss the optimal group size and explain why, given the highly infectious nature of the disease, parallel searches are preferred. We report proof of concept experiments in which a positive sample was detected even when diluted a hundred-fold with negative samples. Using these methods, the costs of mass testing could be reduced by a factor of ten to a hundred or more. If infected individuals are quickly and effectively quarantined, the prevalence will fall and so will the costs of regularly testing everyone. Such a strategy provides a possible pathway to the longterm elimination of SARS-CoV-2. Field trials of our approach are now under way in Rwanda and initial data from these are reported here.Competing Interest StatementThe authors have declared no competing interest.Funding StatementResearch at AIMS is supported in part by the Carnegie Corporation of New York and by the Government of Canada through the International Development Research Centre and Global Affairs Canada. Research at Perimeter Institute is supported in part by the Government of Canada through the Department of Innovation, Science and Economic Development Canada and by the Province of Ontario through the Ministry of Colleges and Universities. Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData presented in Appendix on Methods and Supplementary Information